A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
CABA, Buenos Aires C1062ABK, Argentina
CABA, Buenos Aires C1114AAO, Argentina
CABA, Buenos Aires C1181ACH, Argentina
CABA, Buenos Aires C1425BEI, Argentina
CABA, Buenos Aires F.D., Argentina
Richmond Hil, Ontario L4B 1A5, Canada
Hyderabad, Andhra Pradesh 500008, India
Hyderabad, Andhra Pradesh 500012, India
Dadar (east) Mumbai, Maharashtra 400018, India
Santa Coloma de Gramanet, Catalonia 08923, Spain